Microwave Treatment for Actinic Keratosis

Inclusion Criteria

• •1. Provision of signed and dated informed consent form.
• •2. Stated willingness to comply with all study procedures and availability for the duration of the study.
• •3. Age 18-85 years inclusive (EU); 22-85 years inclusive (US).
• •4. AK lesions for randomization in this study: Clinical diagnosis by a dermatologist of precancerous Actinic Keratosis.
• •5. Cutaneous location.
• •6. 10, 12 or 14 distinct AK lesions (3-6mm in diameter inclusive), for randomization in this study, located on the subjects' scalp or hands (AK lesions on the scalp and hands for randomization cannot be mixed).
• •* There must be at least 2 AK lesions on the left and right side of the scalp or left and right hand.
• •* An even number of distinct AK lesions (10, 12 or 14) are to be selected.
• •* The maximum possible number of available distinct AK lesions should be selected (10, 12 or 14).
• •* The subject may present with any number of AK lesions, however only 10, 12 or 14 distinct AK lesions will be selected for randomization. For example, if a subject presents with 21 AK lesions, an even number of distinct AK lesions are to be selected (i.e. 14 distinct AK lesions with at least 2 distinct AK lesions on the left and right side of the scalp or left and right hand).
• •7. If currently receiving treatment for Actinic Keratosis, agree to stop their current medication for at least 28 days prior to the start of study treatment.
• •8. Agrees to refrain from using any other Actinic Keratosis products or treatments during the study period, unless specified by the Investigator.
• •9. Agrees to refrain from using any topical metallic or ionic treatment (e.g., aluminum chloride, silver nitrate, zinc oxide) during the study period.
• •10. Free of any disease state or condition which, in the investigator's opinion, could impair evaluation of AK or could expose the subject to an unacceptable risk by study participation.
• •11. Able to perform study assessments.